With over 25 years of experience in the industry, Jim Tananbaum is founder and CEO of Foresite Capital that was launched in 2011. The private equity company is dedicated to supporting healthcare-oriented innovations to become profitable and successful by providing them with capital, networks, and relevant information. Although the company received its first institutional capital in 2013, it has been capable of sponsoring various healthcare innovations in sequencing, synthetic biology, and pharmaceuticals such as Aeri, Alder, Aimmune, 10X, Sequenta, Muse Bio, Intellia, Editas, and MindStrong.
Jim Tananbaum earned his M.D and M.B.A from Harvard and M.S. from the Massachusetts Institute of Technology. He also studied math, electrical engineering, and computer science major at Yale. He has been passionate about interdisciplinary sciences for the better part of his life. He also ranked as being among the top 100 investors on Forbes Midas List.
According to Biz Journals, foresite’s most notable deal is Intarcia Therapeutics, which is a major investment in helping diabetes patients control the disease and lose weight. Jim likens the Intarcia type II diabetes implants’ impact to the transformation that the IUD brought to birth control. The product is one of the most recent investments that is expected to launch in the U.S. at the end of 2017. Jim co-founded two other companies namely GelTex Pharmaceuticals and Theravance, Inc., before he founded Foresite Capital. In his portfolio, he was also part of the team that founded Prospect Venture Partners II and III, and Sierra Ventures. You can visit Ideamensch to know more.
The idea behind Forestite Capital was based on amalgamating all aspects of healthcare in a bid to create a novel investment platform. Over the years, he has interacted and made long-term relationships with various leading academicians such as George Whitesides, Rick Klausner, Roy Vagelos, and Rick Levin, among others. Jim believes that the world is going through a period of great change and academicians from different specialities should combine forces in developing insights that will boost the learning and growth of science.